The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 30, 2010

Filed:

Dec. 09, 2003
Applicants:

Andrew M. K. Pennell, San Francisco, CA (US);

James B. Aggen, Burlingame, CA (US);

J. J. Kim Wright, Redwood City, CA (US);

Subhabrata Sen, Sunnyvale, CA (US);

Brian E. Mcmaster, Mountain View, CA (US);

Daniel Joseph Dairaghi, Palo Alto, CA (US);

Valeri V. Martichonok, San Francisco, CA (US);

Inventors:

Andrew M. K. Pennell, San Francisco, CA (US);

James B. Aggen, Burlingame, CA (US);

J. J. Kim Wright, Redwood City, CA (US);

Subhabrata Sen, Sunnyvale, CA (US);

Brian E. McMaster, Mountain View, CA (US);

Daniel Joseph Dairaghi, Palo Alto, CA (US);

Valeri V. Martichonok, San Francisco, CA (US);

Assignee:

ChemoCentryx, Inc., Mountain View, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/496 (2006.01); A61K 31/5377 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 401/14 (2006.01); C07D 409/14 (2006.01);
U.S. Cl.
CPC ...
Abstract

Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.


Find Patent Forward Citations

Loading…